A library of the paired peptide/HLA multimers and artificial APCs allows for construction of a large database of class I-restricted peptides and cognate tumor-reactive TCR genes at an unprecedented scale.

Human NK cells engineered to express a PD-L1 chimeric antigen receptor can control murine and human tumors and reduce myeloid cells expressing high levels of PD-L1.

Tumor immunogenicity is quantified with a novel method, and the resulting tumor immunogenicity score is an effective tumor-inherent biomarker for prediction of response to immune checkpoint inhibitors.

A new, high-throughput in vivo MHC-I peptide minigene library platform shows that the naive immune system cannot eliminate cells presenting immunogenic antigens found at low frequencies within a growing tumor.

A family of engineered immune receptors trigger internalization of cancer cells and antigen-coated targets.

A recently discovered contagious cancer in the Tasmanian devil has the potential to become widespread in the population due to the loss of histocompatibility antigens that are allogeneic to its hosts.

SLAMF6 is an inhibitory checkpoint of T cells, the lack of which leads to better tumor control, suggesting a new immunotherapy target.

Tumor-induced myeloid-derived suppressor cells exert systemic suppression of adaptive immunity by limiting L-selectin-directed trafficking of T cells at vascular checkpoints in lymph nodes.

Killer T cells swarm around tumour targets by accelerating the recruitment of distant T cells, which upon arrival and target engagement augment the chemotactic signal in a positive feedback loop.

The safety and strong antitumor effects of GPC1-specific CAR-T cells against GPC1-expressing solid tumors were demonstrated by using both syngeneic and xenogeneic mouse models.